Every 8-K that Lexeo Therapeutics, Inc. (LXEO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LXEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LXEO filings page.
Lexeo Therapeutics, Inc. reported second quarter 2026 results and highlighted progress across its genetic cardiology pipeline. For the quarter ended June 30, 2026, the company posted a net loss of $25.9 million, or $0.30 per share, compared with a net loss of $26.1 million, or $0.60 per share, a year earlier. Research and development expenses were $19.0 million versus $14.7 million in the prior-year quarter, while general and administrative expenses declined to $9.0 million from $16.0 million. As of June 30, 2026, Lexeo held $234.2 million in cash, cash equivalents and investments, which it believes will fund operations into 2028.
Operationally, Lexeo finalized the protocol and statistical analysis plan for SUNRISE-FA 2, its open-label pivotal trial of LX2006 for Friedreich ataxia cardiomyopathy under an accelerated approval pathway, and initiated the study with first patient enrollment in June 2026, with topline data expected in the second half of 2027 and a potential BLA submission in the first half of 2028. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim Phase I/II data, while reporting that both LX2006 and LX2020 remain generally well tolerated in treated participants.
Lexeo Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders held virtually on June 25, 2026. Stockholders elected three Class III directors—R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley—to serve until the 2029 annual meeting.
Support for the director nominees ranged from 48,792,570 to 64,731,479 votes in favor, with broker non-votes of 9,955,777 on each director. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,497,386 votes for, 55,579 against, and 30,099 abstentions.
Lexeo Therapeutics outlined a pivotal development plan for LX2006, its gene therapy for Friedreich ataxia cardiomyopathy. The company has finalized the SUNRISE‑FA 2 pivotal trial protocol and statistical analysis plan intended to support a Biologics License Application under the FDA’s accelerated approval pathway in the first half of 2028.
SUNRISE‑FA 2 is an open-label study in which 13 adults will receive a single high dose of LX2006 at 1.2x1012 vector genomes per kilogram, compared with 13 untreated controls. The primary endpoint is left ventricular mass index at six months, with key secondary cardiac and neurologic measures. Phase I/II data showed mean LVMI reductions of 18% in participants with abnormal baseline LVMI and 28% in a higher-dose subgroup, and LX2006 has generally been well tolerated across 17 treated participants.
Enrollment for the pivotal trial is expected to begin in the second quarter of 2026, with topline data targeted for the second half of 2027. Lexeo also highlighted its CLARITY‑FA natural history study, continued FDA discussions on confirmatory evidence for full approval, progress in its LX2020 program for PKP2 arrhythmogenic cardiomyopathy, and a cash runway that extends into 2028.
Lexeo Therapeutics reported first quarter 2026 results alongside detailed pipeline updates in an 8-K and investor presentation. The company posted a net loss of $20.2 million, or $0.25 per share, an improvement from a $32.7 million loss a year earlier, driven partly by sharply lower general and administrative expenses.
Cash, cash equivalents and marketable securities were $227.6 million as of March 31, 2026, which Lexeo believes will fund operations into 2028. The update highlights progress for lead cardiac gene therapy programs LX2006 in Friedreich ataxia cardiomyopathy and LX2020 in PKP2 arrhythmogenic cardiomyopathy, including ongoing pivotal‑trial preparations and additional clinical data, and notes a new independent director appointment.
Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.
Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.
Lexeo Therapeutics reported fourth quarter and full year 2025 results and detailed progress across its cardiac gene therapy pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $246.6 million, which it believes will fund operations into 2028.
For 2025, research and development expenses were $63.8 million, down from $74.1 million in 2024, while general and administrative expenses rose to $45.5 million from $31.7 million, reflecting growth investments. Net loss for 2025 was $100.0 million, or $1.86 per share, broadly similar to 2024.
Operationally, Lexeo advanced lead programs LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2 arrhythmogenic cardiomyopathy, including positive interim data, FDA alignment on the SUNRISE‑FA 2 pivotal trial design, and preparation for a Biologic License Application for LX2006. The company also highlighted a research collaboration with Johnson & Johnson on targeted cardiac delivery of AAV gene therapy and a previously executed $154 million equity financing to support its expanding cardiovascular pipeline.
Lexeo Therapeutics, Inc. reported a leadership change in its research function. Effective February 1, 2026, Dr. Adler stepped down as Head of Research and entered into a Transition and Consulting Agreement with the company. He will continue providing advisory services during a transition period lasting until the earlier of July 31, 2026 or earlier termination.
During this transition period, Dr. Adler will receive up to $62,500 in monthly installments, and his service-vesting equity awards will continue to vest as he provides services. The company also extended his deadline to exercise vested stock options to six months after the transition period ends. If he signs a supplemental release of claims after the transition period, he will receive an additional $1,000 lump sum payment.
Lexeo Therapeutics, Inc. reported senior leadership changes, adding operational and medical depth to its management team. The board appointed Jose Manuel Otero, Ph.D., the current Chief Technical Officer, as Chief Operating Officer effective January 2, 2026, with an approved annual base salary of $510,000. The company states there are no special arrangements, family relationships, or related-party transactions tied to his appointment.
Lexeo also appointed Narinder P. Bhalla, M.D. as Chief Medical Officer effective January 20, 2026, succeeding Eric Adler, M.D., the Company’s Head of Research. Dr. Adler will no longer be an executive officer as of January 27, 2026, and will serve as President and Chief Executive Officer of Myoventive, Inc. while remaining a senior clinical and scientific advisor to Lexeo.
Lexeo Therapeutics, Inc. reported positive interim Phase 1/2 clinical data for its gene therapy candidate LX2020 in PKP2-associated arrhythmogenic cardiomyopathy. On January 12, 2026, the company issued a press release describing these results and scheduled a conference call and webcast at 8:00 a.m. ET the same day to discuss the interim data. Lexeo also posted an updated LX2020-focused corporate presentation and a broader corporate presentation on its website, both of which, along with the press release, are attached as exhibits. The report includes standard cautionary language that future clinical progress, regulatory outcomes, and the company’s liquidity and capital resources are subject to significant risks and uncertainties.
Lexeo Therapeutics (LXEO) furnished an 8-K announcing it issued a press release with business highlights and financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference. The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed filed under the Exchange Act. LXEO’s common stock trades on the Nasdaq Global Market.
Lexeo Therapeutics priced a public offering of 15,625,000 common shares at $8.00 per share, with underwriters purchasing at $7.52. The company granted a 30‑day option for up to 2,343,750 additional shares. Gross proceeds are expected to be approximately $125 million before fees, with closing targeted for October 20, 2025.
Separately, Lexeo agreed to sell 1,250,015 pre‑funded warrants in a private placement for approximately $10 million; the warrants are immediately exercisable at $0.0001 per share and include a 9.99% beneficial ownership cap, adjustable up to 19.99%. As of September 30, 2025, the company estimated $122.8 million in cash, cash equivalents and investments.
Clinical updates: for LX2006, the FDA indicated openness to an accelerated approval BLA using pooled Phase I/II and pivotal data, contingent on enhanced comparability and nonclinical requirements. For LX2020, nine participants have been dosed; the program has been generally well tolerated with one Grade 3 serious adverse event possibly treatment related. Additional safety and efficacy data are expected in January 2026.
Lexeo Therapeutics, Inc. reported regulatory updates and clinical progress for its gene therapy candidate LX2006 for Friedreich ataxia cardiomyopathy. The company received FDA feedback on key components of a potential accelerated approval pathway for LX2006 and highlighted positive interim Phase 1/2 clinical data in this indication. On October 7, 2025, Lexeo issued a press release detailing these developments and scheduled a conference call and webcast at 8:00 a.m. ET the same day to discuss the regulatory updates and interim data. The corporate presentation and press release are furnished as exhibits to provide more detail on the program and pathway.
Lexeo Therapeutics announced a planned CFO transition: Louis Tamayo will become Chief Financial Officer effective August 15, 2025, succeeding Dr. Kyle Rasbach, who will provide transition support through August 29, 2025. Mr. Tamayo joins with senior finance experience at Siemens Healthineers, Becton Dickinson and Pfizer.
Mr. Tamayo's initial compensation includes a $480,000 base salary, a discretionary target cash bonus equal to 40% of base salary, 45,000 RSUs and options to purchase 280,000 shares with standard multi-year vesting. Termination protections provide a lump-sum payment equal to 12 months' base salary and up to 12 months of COBRA reimbursement; enhanced change-in-control provisions add a year’s target bonus, COBRA and equity acceleration. Dr. Rasbach will receive a $128,000 lump sum and accelerated vesting of 40,466 options, and his resignation was stated to not result from any disagreement with the company.